Form 4: Neurocrine CSO's Stock Vesting & Tax Withholding

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, reported the vesting of 4,426 restricted stock units and the subsequent withholding of 2,248 shares for tax obligations.

Summary

• Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences Inc. (NBIX), reported transactions related to company common stock.
• On November 29, 2025, 4,426 shares of common stock were acquired upon the vesting of restricted stock units (RSUs).
• Concurrently, 2,248 shares were disposed of at a price of $152.16 per share to satisfy tax withholding requirements related to the RSU vesting.
• Following these transactions, Jude Onyia beneficially owns 15,881 shares of Neurocrine Biosciences common stock.
• The RSUs were originally granted on November 29, 2021, and vested in tranches, with the final tranche of 4,426 shares vesting on November 29, 2025.

Sentiment

Score: 7

Explanation: This is a routine executive compensation event (RSU vesting) with no discretionary sales, indicating continued alignment of executive interests with the company's long-term performance. It is a neutral to slightly positive signal regarding executive retention.

Positives

• The vesting of 4,426 restricted stock units (RSUs) indicates continued compensation and retention of a key executive, aligning their interests with long-term company performance.
• The disposition of shares was solely for tax withholding purposes, not a discretionary sale by the officer, suggesting continued confidence in the company's stock.

Negatives

• No direct negative implications are apparent from this routine compensation and tax-related transaction.

Risks

• NA

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance.

Management Comments

• NA

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context. It reflects standard executive compensation practices within the biotechnology sector, where equity awards like RSUs are common for aligning executive interests with shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice across the biotechnology and pharmaceutical industries, aligning executive incentives with long-term company performance.
• The withholding of shares to cover tax obligations upon RSU vesting is also a common and compliant method for managing tax liabilities associated with equity compensation, consistent with practices at comparable companies such as Amgen Inc. (AMGN) or Gilead Sciences, Inc. (GILD).

Stakeholder Impact

• Shareholders: The vesting of RSUs is a standard component of executive compensation, aligning management's interests with long-term shareholder value. The tax withholding is a routine administrative event and does not represent a discretionary sale.
• Employees: Reflects standard equity compensation practices for key personnel within the company.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU vesting and tax withholding) and does not provide new information that would fundamentally alter the investment thesis for Neurocrine Biosciences. It confirms the ongoing compensation structure for a key officer but offers no insights into operational performance, strategic shifts, or financial results that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

NBIX, Neurocrine Biosciences, Jude Onyia, Form 4, insider transaction, RSU vesting, stock compensation, Chief Scientific Officer